29 April 2021
\n \n \n \nAlchemab Therapeutics, the antibody therapeutic start-up backed by SV Health Investors, has graduated from the BioEscalator after 18 months in the Innovation Labs.
\n \n\n \n \n26 April 2021
\n \n \n \nMoA Technology, a spin-out company from Oxford University\u2019s Department of Plant Sciences, has secured an additional \u00a35M funding for its series A round to support the expansion and acceleration of its discovery programme.
\n \n\n \n \n16 April 2021
\n \n \n \nThe biotech company, which joined the BioEscalator Innovation Lab as a new start-up in December 2019, secures Series A funding to advance its novel platform for identifying disease-modifying antibody therapeutics.
\n \n\n \n \n23 March 2021
\n \n \n \n\n \n \n10 March 2021
\n \n \n \nAccunea is pioneering the next generation of continuous, real-time organ function monitoring to ensure every transplant counts.
\n \n\n \n \n26 February 2021
\n \n \n \nBioEscalator biotech, MediMab Biotherapeutics, secures Series A funding to advance two immuno-oncology candidate therapeutics in pre-clinical studies.
\n \n\n \n \n12 January 2021
\n \n \n \nThe partnership deal, worth over \u20ac876M, will enable Enara Bio to lead the discovery and validation of Dark Antigens to target lung and gastrointestinal cancers.
\n \n\n \n \n6 January 2021
\n \n \n \nTheolytics raises \u00a35M ($6.8M) Series A round co-led by Epidarex Capital and Taiho Ventures to advance viral cancer therapies.
\n \n\n \n \n9 December 2020
\n \n \n \nEnara Bio relocates to The Oxford Science Park\u2019s newest facility to expand R&D capabilities in the search for novel cancer immunotherapies.
\n \n\n \n \n9 December 2020
\n \n \n \nRA Capital Management leads $45M Series A financing for PepGen\u2019s next-generation oligonucleotide platform targeting Duchenne muscular dystrophy and other rare neuromuscular and cardiac diseases. PepGen\u2019s proprietary cell-penetrating peptide technology promises enhanced safety, efficacy, and improved delivery to cardiac muscle; Oxford Sciences Innovation, The University of Oxford, and CureDuchenne Ventures also participated in the Series A round.
\n \n\n \n \n28 October 2020
\n \n \n \nWe are excited to announce that one of our resident companies, Base Genomics, has been acquired by Exact Sciences for $410 million. The acquisition will undoubtedly further propel Base Genomics' groundbreaking technology alongside Exact Sciences' existing expertise, ultimately enhancing cancer diagnostics.
\n \n\n \n \n5 October 2020
\n \n \n \nNovel therapeutics company, Alchemab Therapeutics, has been shortlisted in the Best Start-Up category of the 12th Annual OBN Awards.
\n \n\n \n \n30 September 2020
\n \n \n \nAlchemab announced a strategic partnership with the Alberta Machine Intelligence Institute (Amii) to accelerate its adoption of artificial intelligence.
\n \n\n \n \n14 July 2020
\n \n \n \nThree companies at Oxford\u2019s BioEscalator are developing new detection methods and have discovered potential therapeutics in the fight against COVID-19.
\n \n\n \n \n1 July 2020
\n \n \n \nRapidly growing immune cell regulation company relocates to The Oxford Science Park
\n \n\n \n \n22 June 2020
\n \n \n \nErvaxx rebrands as Enara Bio to reflect a broader emphasis on the discovery and development of novel TCR-based cancer immunotherapies.
\n \n\n \n \n22 June 2020
\n \n \n \nThe BioEscalator celebrated the success of its recent Pitch Finale event as Theolytics emerged as the winner, securing a spot in the final of BIO International Start-up Stadium.
\n \n\n \n \n2 June 2020
\n \n \n \nBase Genomics announces the company's launch with $11M to commercialise epigenetic technology for early and sensitive cancer detection from a liquid biopsy.
\n \n\n \n \n26 May 2020
\n \n \n \nMediMabBio, an immuno-oncology development company, has established a base at the BioEscalator and will expand R&D through collaborative research with local researchers.
\n \n\n \n \n20 October 2019
\n \n \n \nMoA Technology, borne out of Oxford University research, launches to confront the global herbicide\r\nresistance crisis. The Company launches with \u00a36.3m Series A funding round.
\n \n\n \n \n